Citations 1
Ibrutinib plus obinutuzumab as frontline therapy for chronic lymphocytic leukemia is associated with a lower rate of infusion-related reactions and with sustained remissions after ibrutinib discontinuation: a single-arm, open-label, phase 1b/2 clinical tri
Lengerke-Diaz, Paula A. , Velez-Lujan, Juliana, Choi, Michale Y., Moreno-Cortes, Eider , Forero-Forero, José Vicente , García-Robledo, Juan Esteban , Jacobs, C , McCarthy, Colin, Heinen, Alaina, Amaya-Chanaga, Carlos I., Forero, Jose V , Garcia-Robledo, Juan Esteban , Diaz, Paula A Lengerke , Castro, Januario E. , Jacobs, Chaja, Kipps, Thomas J.
No container title available | September 14, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract Ibrutinib-based therapies are costly and require continuous administration. We hypothesized combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep remissions allowing discontinuation. We enrolled 32 therapy-naïve CLL patients to receive ibrutinib plus obinutuzumab, followed by single-agent ibrutinib. Patients could discontinue ibrutinib after 36 months with sustained complete response (CR). We evaluated treatment safety, efficacy, and outcomes after ibrutinib discontinuation. The overall response rate was 100%, 28% achieved a CR, and 12.5% achieved bone marrow undetectable minimal residual disease. At a three-year median follow-up, 91% remain in remission with 100% overall survival. Five patients in sustained CR stopped ibrutinib and have not progressed. Eight non-CR patients discontinued for other reasons, with only two progressing. The treatment was safe, with a lower IRR rate. All patients responded to treatment with longer time-to-progression after discontinuation of ibrutinib. Our data support the evaluation of ibrutinib discontinuation strategies in more extensive clinical trials.